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Introduction
The myeloproliferative neoplasms (MPNs) are a group of
haematological diseases in which cells of the myelo-erythroid
lineage are overproduced (Dameshek, 1951). Apart from chronic
myelogenous leukaemia, the three most common MPNs are
polycythaemia vera (PV), essential thrombocythaemia (ET) and
primary myelofibrosis (PMF). The clinical features of these diseases
are the overproduction of mature, functional blood cells, specifically
characterised by an increased red-cell mass in PV, a high platelet
count in ET and bone marrow fibrosis in PMF (Levine et al., 2007;
Spivak et al., 2003). In 2005, several groups reported a somatically
acquired gain-of-function mutation (V617F) in the JAK2 tyrosine
kinase in MPN patients (Baxter et al., 2005; James et al., 2005; Jones
et al., 2005; Kralovics et al., 2005; Levine et al., 2005; Zhao et al.,
2005). The V617F mutation was found in virtually all PV patients
and ~50-60% of ET and PMF patients. It was also detected at low
incidence in other MPNs, but not in solid cancers (Scott et al., 2005;
Steensma et al., 2005).
The V617F mutation disrupts the inhibitory activity of the JAK2
pseudokinase domain, leading to constitutive JAK2 kinase activity
and hyperactivation of multiple downstream targets (James et al.,
2005). It remains unclear how this single mutation can associate
with three different diseases. Cell-extrinsic factors, such as serum
erythropoietin levels and depleted iron stores, have been suggested
to constrain erythropoiesis in ET patients bearing the JAK2V617F
mutation (Campbell et al., 2005). Cell-intrinsic factors, such as
differential STAT1 activation in ET compared with PV patients,
have also been identified (Chen et al., 2010). In addition, inherited
genetic modifiers have been suggested to have a role in varying the
disease phenotype (Campbell et al., 2005; Pardanani et al., 2006).
Interestingly, most PV patients harbour subclones that are
homozygous for the JAK2V617F mutation, whereas this is
extremely rare in ET (Scott et al., 2006). Consistent with this, dosage
and strength of signalling of the JAK2V617F allele have been
implicated in the polycythaemic phenotype seen in PV patients
(Passamonti and Rumi, 2009; Tiedt et al., 2008).
Early X-linked polymorphism studies indicated that MPNs were
clonally derived and that their pathogenesis was probably the result
of a transforming event in a haematopoietic stem cell (HSC) or
early multipotent progenitor (Fialkow, 1979). Through improved
functional assays and advances in techniques for HSC isolation via
multiparameter flow cytometry, the JAK2V617F mutation has been
detected in primitive Lin–CD34+CD38–CD90+ cells (Jamieson et
al., 2006), several types of haematopoietic progenitors (e.g. GMP,
BFU-e) (Baxter et al., 2005) and in CD34+CD38– cells, which are
capable of reconstituting immunodeficient mice (James et al., 2008).
Despite its clear role in MPNs, JAK2V617F is not always the
initiating lesion, because it has been shown in some patients to be
preceded by other genetic changes (i.e. mutations in TET2 or
deletion of chromosome 20) (Delhommeau et al., 2009; Schaub et
al., 2009). However, given the prevalence and specificity of the
JAK2V617F mutation to the MPNs, substantial effort has been
made in the last few years to create mouse models in which
JAK2V617F is introduced in an effort to evaluate the functional
consequences of the mutation in vivo and to understand
mechanisms underlying the initiation and progression of MPNs.
This Commentary briefly summarises the early attempts to model
JAK2V617F-associated diseases in mice using bone marrow
transplantation approaches and mouse transgenesis (Table 1), and
then discusses in more detail the more recently published
homologous recombination-derived knock-in models (Table 2).
Bone marrow transplantation models of JAK2V617F-
associated MPNs
Using retroviruses to overexpress a gene of interest is a highly
versatile method for modelling haematopoietic malignancies. It is
relatively quick compared with other genetic techniques and allows
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In 2005, several groups identified a single gain-of-
function point mutation in the JAK2 kinase that was
present in the majority of patients with
myeloproliferative neoplasms (MPNs). Since this
discovery, much effort has been dedicated to
understanding the molecular consequences of the
JAK2V617F mutation in the haematopoietic system.
Three waves of mouse models have been produced
recently (bone marrow transplantation, transgenic and
targeted knock-in), which have facilitated the
understanding of the molecular pathogenesis of
JAK2V617F-positive MPNs, providing potential platforms
for designing and validating novel therapies in humans.
This Commentary briefly summarises the first two types
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targeting of a specific cell population. However, there are also
several conceptual shortfalls with the approach – for example, the
ubiquitous and/or non-physiological expression levels obtained, as
well as position-effect differences in expression between transgene
integration sites. Nevertheless, generating models using this
method is a powerful and efficient approach for defining the impact
of specific genetic changes on the phenotypes in vivo.
Several groups have reported that transplantation of mice with
bone marrow cells retrovirally transduced with JAK2V617F results
in a myeloproliferative phenotype with many characteristics of PV,
including marked erythrocytosis, splenomegaly, extramedullary
haematopoiesis and cytokine-independent progenitor growth
(Bumm et al., 2006; Lacout et al., 2006; Wernig et al., 2006;
Zaleskas et al., 2006) (for a review, see Morgan and Gilliland, 2008).
Interestingly, platelet counts were reported to be normal in most
of these studies, despite abundant transgene expression in
megakaryocytes. Many mice also appeared to undergo evolution
to a myelofibrosis-like disease with associated anaemia,
leukocytosis and marrow fibrosis with neutrophilia, although the
extent of disease transformation was variable depending on the
strain background of the transplanted mice. Additional factors
compounding the variable disease presentation could include
differences in viral integration sites, the level of transgene
expression and the cell population targeted by the viruses in
different cohorts. Nevertheless, these bone marrow transplantation
studies provided the first data demonstrating that JAK2V617F
expression is sufficient to induce an MPN-like phenotype in mice.
Transgenic models of JAK2V617F-associated MPNs
The next series of mouse models were derived by pronuclear
injection, creating stable transgenic lines of mice expressing
JAK2V617F, the first of which was generated by Shide and co-
workers (Shide et al., 2008). In this study, ectopic expression of the
cDNA encoding mouse JAK2V617F under the control of the H2Kb
promoter was associated with erythrocytosis, thrombocytosis and
eventual myelofibrosis. Similar findings were later reported
following overexpression of the cDNA encoding human JAK2V617F
under the control of the Vav promoter (Xing et al., 2008). In the
latter study, a second transgenic line exhibited only a mild increase
in these myelo-erythroid lineages. Interestingly, this was associated
with similar expression levels of the human JAK2V617F transgene
compared with the level of endogenous mouse Jak2.
Soon thereafter, Tiedt and colleagues took an innovative
approach to drive variable levels of human JAK2V617F expression
in an inducible manner (Tiedt et al., 2008). A mouse line was
generated by microinjection that carries nine copies of a bacterial
artificial chromosome (BAC) (containing human JAK2 exons 1-12
with the 5 regulatory region) followed by a cDNA fragment (exons
13-25 with SV40 polyA, encoding the mutant human JAK2 kinase
domains) placed in the inverse orientation and flanked by
antiparallel lox66 and lox71 sites. This line expresses the human
JAK2V617F under the control of the minimal human JAK2
promoter when crossed with mice that express Cre recombinase,
giving rise to different JAK2V617F expression levels depending on
the amount of Cre activity. Specifically, mice in which JAK2V617F
expression was induced by a haematopoietic Vav-Cre transgene
expressed lower levels of human mutant JAK2V617F than
endogenous wild-type mouse JAK2 and developed thrombocytosis
with strongly elevated platelet counts, moderate neutrophilia and
unchanged haematocrit. However, mice in which JAK2V617F
expression was induced by Mx1-Cre [where Cre expression is
transient and the levels of Cre expression can be controlled by dose-
dmm.biologists.org312
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Table 1. Retroviral overexpression, transplantation and transgenic mouse model phenotypes
A. Retroviral overexpression and bone marrow transplantation models
V617F
species Recipient Hct (%) Platelets WBC MF Reference
BALB/c 73.7±6.5 (VF) 49.7±4.3 (WT) ~2-fold increase ~17-fold increase YesMouse
C57Bl/6 72.5±3.8 (VF) 44.9±2.5 (WT) Normal ~2-fold increase No
Wernig et al., 2006
Mouse C57Bl/6 61±7 (Group 1; VF)
57±7 (Group 2; VF)
Values not shown Normal Increased Yes Lacout et al., 2006
BALB/c ~70 (mean; VF) ~40 (mean; WT) Normal Increased YesMouse
C57Bl/6 ~65 (mean; VF) ~47 (mean; WT) Normal Mild increase Yes
Zaleskas et al., 2006
Mouse BALB/c ~83 (median; VF) – Normal Increased Yes Bumm et al., 2006
B. Transgenic models
V617F
species Construct Activation Hct (%) Hb (g/l) Platelets ( 109/l) WBC ( 109/l) MF Reference
















































a,bTwo different founder lines developed by Shide et al. (2008). c,dTwo different founder lines developed by Xing et al. (2008). Hb, haemoglobin; Hct, haematocrit; MF, myelofibrosis;
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dependent activation of the Mx1 promoter with polyinosine-
polycytosine (pIpC)] generally retained higher JAK2V617F
transgene copy number than in the Vav-Cre model and displayed
increased erythrocytosis as well as thrombocytosis. These results
are consistent with the hypothesis that the level of JAK2V617F
expression correlates with MPN subtype, where higher doses of
JAK2V617F expression are usually associated with PV.
Knock-in models of JAK2V617F-associated MPNs
Increasing evidence has indicated that the timing of oncogene
activation, the cell type(s) in which it is activated and the level at
which it is expressed are crucial to modelling human leukaemic
malignancies (Ren, 2004). Analysis of patient samples has indicated
that the dosage of JAK2V617F expression correlates with different
disease subtypes; in particular, homozygous mutations are mostly
detected in PV and rarely in ET (Barbui et al., 2004; De Stefano et
al., 2010; Scott et al., 2006). The retroviral transduction and
transgenic models discussed above have clearly demonstrated the
importance of JAK2V617F in myeloid malignancies, and the
observed phenotypic variability probably reflects the positional
effect of the transgene integration sites and consequences of high
transgene copy number. To dissect precisely the pathogenesis of
MPN initiation and progression, it is important to express
JAK2V617F at a physiological level and in the correct spatio-
temporal expression pattern. This can be achieved by introducing
the JAK2V617F mutation under the control of the endogenous Jak2
Disease Models & Mechanisms 313
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aDonor (D) and recipient (R) backgrounds are shown in parentheses. BFU-e, burst forming unit-erythroid; BM, bone marrow; BMT, bone marrow transplantation; CFU-e, colony
forming unit-erythroid; D, donor; EECs, endogenous erythroid colonies; G, CFU-G (granulocytes); GEMM, CFU-GEMM (granulocyte, erythrocyte, macrophage, megakaryocyte); GM,
CFU-GM (granulocyte, macrophage); Hct, haematocrit; Het., heterozygous; Hom., homozygous; M, CFU-M (macrophage); MF, myelofibrosis; NA, not applicable; Plt, platelets; R,
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promoter via homologous recombination in embryonic stem (ES)
cells. This approach allows JAK2V617F to be expressed at a
physiological level and only in haematopoietic tissues, thereby
mimicking the acquisition of the JAK2V617F mutation in human
disease. Recently, several such knock-in models have been
generated via homologous recombination in ES cells and express
JAK2V617F from the endogenous Jak2 promoter (Fig. 1A) (Akada
et al., 2010; Mullally et al., 2010; Marty et al., 2010; Li et al., 2010).
dmm.biologists.org314
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Fig. 1. Genetic strategies for generating mouse models of JAK2V617F-positive MPNs, and the phenotypic characteristics of each. (A)Schematic
representation of the targeting strategies of four knock-in models. In the Akada et al. (Akada et al., 2010) model (1), the conditional knock-in allele was generated
by introducing a V617F mutation construct including the floxed Jak2 cDNA (exons 13-24) with a PGK-Neo-stop cassette in intron 12 of the mouse Jak2 gene.
Upon Cre recombination and removal of the floxed sequence, mouse JAK2V617F was expressed under the control of the endogenous mouse Jak2 regulatory
elements. In the model by Mullally et al. (Mullally et al., 2010) (2), the conditional knock-in allele was engineered to have a point mutation in exon 13 of the
mouse Jak2 gene (numbered 14 in the figure) and, upon flippase (removal of Neo) and Cre (removal of wild-type exon 14) recombination, the mouse JAK2V617F
was expressed under the control of the endogenous mouse Jak2 regulatory elements. In the Marty et al. (Marty et al., 2010) model (3), the constitutive knock-in
allele was engineered to have a point mutation in exon 13 of the mouse Jak2 gene with a PGK-Neo cassette flanked by flippase recognition target (FRT) in intron
13. The PGK-Neo cassette can be removed by flippase recombination. In the Li et al. (Li et al., 2010) model (4), the conditional knock-in allele was generated by
inserting a floxed PGK-Neo-polyA-stop cassette preceding the human JAK2V617F cDNA into the translation start site in exon 2 of the mouse Jak2 locus. Upon Cre
recombination, human JAK2V617F was expressed under the control of the endogenous mouse Jak2 regulatory elements. Red asterisks indicate where the
mutation is introduced. (B)Approximate increase (relative to normal control) in haematocrit (x-axis) and platelet counts (y-axis) for the transplantation, transgenic
models and knock-in mouse models. Open data points indicate studies using human JAK2V617F, whereas filled symbols are studies that use mouse JAK2V617F.
The shaded red area indicates models that exhibit a PV-like phenotype and the shaded blue area indicates models that resemble an ET-like phenotype. See
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Akada and colleagues first reported a conditional mouse
model in which the mouse JAK2V617F expression was controlled
by the endogenous Jak2 promoter and could be experimentally
induced by pIpC treatment (Akada et al., 2010). The knock-in
allele was generated by introducing a V617F mutation construct
including the floxed Jak2 cDNA exons 13-24 with a PGK-Neo-
stop cassette in intron 12 of mouse Jak2. Following pIpC
treatment of adult mice, heterozygous mice developed a PV-like
phenotype, including markedly increased haemoglobin,
haematocrit, red blood cells, leukocytosis, thrombocytosis,
splenomegaly, reduced serum erythropoietin (Epo) levels and
Epo-independent erythroid colonies. Expression of mRNA
encoding the JAK2V617F mutant was only 50% of wild-type
levels. Mice homozygous for JAK2V617F also developed a PV-
like disease associated with significantly greater reticulocytosis,
leukocytosis, neutrophilia and thrombocytosis; marked
expansion of erythroid progenitors and Epo-independent
erythroid colonies; larger spleen size; and accelerated bone
marrow fibrosis compared with heterozygous JAK2V617F mice.
Of particular note, haemoglobin levels of mice homozygous for
JAK2V617F were similar to, or even lower than, those of
heterozygous mice, but the platelet counts were considerably
increased compared with those in the heterozygous mice. These
observations contrast with the current patient data suggesting
that JAK2V617F homozygosity is associated with PV and not ET
(Scott et al., 2006). Mice with expression of both heterozygous
and homozygous JAK2V617F showed significantly expanded
haematopoietic stem and progenitor cell compartments in bone
marrow and spleen, as determined by increased frequency of
Lin–Sca1+cKit+ (LSK) and myeloid progenitor populations.
Next, Marty and co-workers and Mullally and colleagues
independently reported mouse JAK2V617F knock-in models with
expression of mouse JAK2V617F under the control of the
endogenous promoter. Both mouse lines were engineered to have
a point mutation in exon 13 of the mouse Jak2 gene, with
JAK2V617F germline expression in a constitutive knock-in (Marty
et al., 2010), or in a conditional knock-in activated by breeding the
mice with E2A transgenic Cre mice (Mullally et al., 2010). Both
models displayed marked PV-like phenotypes characterised by
erythrocytosis, leukocytosis, splenomegaly and reduced survival.
However, distinct features were also observed between the two
models (Table 2). The model reported by Marty and colleagues
demonstrated markedly increased megakaryopoiesis, as
determined by the presence of giant platelets and a 4.7-fold increase
in overall platelet counts. Both bone marrow and spleen displayed
myeloid tri-lineage hyperplasia, and there was an increase in
erythroid (88-fold) and myeloid (82-fold) precursors in spleen. Most
animals survived to develop advanced fibrosis in these organs at
around 9 months of age. By contrast, the model reported by Mullally
and colleagues displayed a lethal MPN with a median survival of
146 days. The mutant mice did not exhibit elevated platelet counts
and no differences were observed in megakaryocyte ploidy,
although a mild increase in megakaryocytes was observed in the
spleen and CD41+ cells were increased in bone marrow. White
blood cell counts were elevated, but there was not an obvious
increase in the size of Mac1+Gr1+ or Mac1+ myeloid cell
populations. Reticulin fibrosis was absent in both bone marrow
and spleen, even in older cohorts (>6 months of age).
The final model, reported by Li and co-workers, was a
conditional knock-in model that expresses the human JAK2V617F
(Li et al., 2010). This allele was generated by inserting a floxed PGK-
Neo-poly(A) transcriptional stop cassette preceding the cDNA
encoding human JAK2V617F into the translation start site in exon
2 of the mouse Jak2 locus (JAK2F/+ allele). This targeted allele was
designed to disrupt the wild-type Jak2 expression and result in a
1:1 expression ratio of mouse JAK2 to human JAK2V617F.
Heterozygous mice expressing human JAK2V617F were obtained
by crossing mice carrying the JAK2F/+ allele with Mx1-Cre mice.
Six weeks following pIpC injection, mice with JAK2V617F
expression displayed mildly elevated platelet counts together with
significantly higher haemoglobin levels, but white blood cell counts
were not significantly changed, which is reminiscent of human
JAK2V617F-positive ET. These phenotypes were supported by
increased terminal erythroid and megakaryocytic differentiation
together with increased numbers of lineage-restricted progenitors
in the bone marrow. Splenomegaly was not observed and there was
no increase in reticulin staining in both spleen and bone marrow,
even in older mice. Notably, as in human ET, approximately 10%
of JAK2V617F mice observed for more than 26 weeks after pIpC
treatment developed either PV-like disease with marked
erythrocytosis or bone marrow fibrosis.
JAK2V617F in stem and progenitor cells
Importantly, Mullally and colleagues and Li and colleagues further
characterised the haematopoietic hierarchy to clarify the impact
of JAK2V617F on the various stages of haematopoietic
differentiation. In the model generated by Mullally et al.,
quantitative evaluation of bone marrow stem and progenitor
populations showed an increase in myeloid progenitors
(Lin–Sca1–cKit+), which was largely attributed to an expansion of
the megakaryocytic and erythroid progenitor (MEP) subpopulation.
However, the frequency of HSC-enriched LSK (Lin–Sca1+cKit+)
cells was not altered, which is in contrast to what was observed in
the first model reported by Akada and colleagues. There were
also  no changes in the frequencies of long-term HSCs
(CD150+CD48–LSK). Although the JAK2V617F mutation has been
detected in HSC-enriched populations of human MPN patients
(Jamieson et al., 2006), there were no observed functional
consequences in LSK cells, such as differences in cell cycling (as
measured by BrdU and 7AAD incorporation) or JAK-STAT
signalling (as measured by flow cytometric analysis of
phosphorylated STAT5). Furthermore, microarray analysis showed
that mutant LSK cells were highly similar to wild-type LSK cells
with respect to gene expression, although an enrichment of the
erythroid, myeloid and megakaryocytic differentiation pathways
was noted, suggesting an increase in the likelihood of myeloid
differentiation by cells in the LSK compartment. Bone marrow
transplantation experiments demonstrated that the disease
phenotypes were transplantable, and that the disease-initiating cell
population is contained within the HSC-enriched LSK population
but not in the committed myeloid progenitors. Competitive
transplantation experiments demonstrated that JAK2V617F LSK
cells confer, at most, a minor selective advantage (Mullally et al.,
2010).
By contrast, Li and colleagues found that JAK2V617F mice aged
over 6 months after pIpC injection had reduced numbers of LSK
Disease Models & Mechanisms 315
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cells, which exhibited increased DNA damage, reduced cell cycling
and reduced apoptosis. This finding contrasts with the notion that,
in patients, following acquisition of the JAK2V617F mutation, HSCs
might acquire a subtle selective advantage that allows clonal
outgrowth over time. Furthermore, in the model generated by Li
et al., non-competitive bone marrow transplantation experiments
showed a progressive reduction of donor chimerism of JAK2V617F
in recipients, indicating a decreased stem cell activity in cells
expressing JAK2V617F compared with wild-type littermate
controls. Consistent with this, direct comparison of the wild-type
versus JAK2V617F bone marrow cells in competitive
transplantation experiments demonstrated that JAK2V617F confers
a mild but significant disadvantage to HSCs, an effect that was most
striking in secondary transplantations.
In summary, all four models involving a heterozygous knock-in
allele displayed a transplantable myeloproliferative disease. The
models expressing a heterozygous mouse JAK2V617F all had a PV-
like phenotype, whereas the model expressing heterozygous human
JAK2V617F was associated with ET with a low-level progression
to PV and myelofibrosis. As summarised in Table 2, these models
demonstrate many similar features but also have interesting
differences that impact our understanding of haematopoiesis and
MPNs.
Moving forward
Tremendous efforts have been undertaken to model the
JAK2V617F mutation in mice since its identification in human
MPNs in 2005. To better understand disease initiation, progression,
and even transformation, it is informative to compare the
phenotypes of JAK2V617F mice between these models, in
particular the recent knock-in models that were designed to
express the mutant protein at a pathophysiological level. Through
these models, it is clear that JAK2V617F mutation is sufficient to
drive the disease phenotypes observed in patients and that the
severity of the phenotype is sensitive to the levels of JAK2V617F
expression (Fig. 1B). The bone marrow retroviral transduction and
transplantation studies were perhaps most instructive in their
demonstration of a clear PV-like phenotype, showing the impact
that this single point mutation can have on the haematopoietic
system (Bumm et al., 2006; Lacout et al., 2006; Wernig et al., 2006;
Zaleskas et al., 2006). Importantly, transgenic mice that brought
the dose closer to normal physiological levels, with JAK2V617F
expression under the control of either the minimal human JAK2
promoter, or the H2Kb or Vav promoters, gave the field important
information on how JAK2V617F produces variable phenotypes
resembling ET, PV or both, depending on the levels of JAK2V617F
expression (Shide et al., 2008; Tiedt et al., 2008; Xing et al., 2008).
The mechanisms responsible for these differences are not entirely
clear, but might include integration-site-related position effects,
clonal variation in transgene copy number or loss of 3 Jak2 cis-
regulatory elements.
The recent knock-in mouse models all demonstrated a
myeloproliferative phenotype: all three models expressing the
mouse heterozygous JAK2V617F exhibited a PV-like phenotype,
whereas the model expressing the human JAK2V617F exhibited
an ET-like phenotype. The reasons for these phenotypic differences
are currently unclear, but could be related to inherent differences
in the human and mouse JAK2V617F protein, differences between
the mouse and human environments, or the different targeting
strategies used.
First, there might be inherent differences in kinase activity
between the two species when V617F is introduced. Although
expression of the mouse JAK2V617F results in a ligand-
independent phosphorylation of downstream pathways [i.e.
erythroblasts (Akada et al., 2010) and bone marrow (Marty et al.,
2010)], expression of the human JAK2V617F only gave rise to Epo-
hypersensitive cells [as measured by phosphorylated STAT5 in
erythroblasts (Li et al., 2010)]. It is possible, therefore, that the
V617F mutation dysregulates kinase function to a different extent
when introduced into the human versus the mouse protein. Second,
human and mouse might differ with respect to JAK2V617F-
interacting partners or binding and/or activation properties (e.g.
receptors, signal transducers or transcription factors) or the
downstream response to the aberrant JAK2 signal, resulting in
stronger signalling consequences in mouse models compared with
patients, resulting in a PV-like rather than an ET-like phenotype
in mice. Also, differences in mouse strains and targeting strategies
might be responsible for the differences observed.
Interestingly, Li and co-workers reported a relatively mild
phenotype in the human JAK2V617F-expressing model, which is
consistent with many aspects of human ET, including a 5-10% rate
of disease transformation to PV or myelofibrosis (Li et al., 2010).
In those mice that transformed to PV or myelofibrosis, it is
presumed that an additional genetic event must occur to drive
enhanced signalling and/or other cellular processes. Indeed, other
genetic alterations have been found in human MPNs in addition
to JAK2V617F, such as mutations in TET2, MPL, ASXL1, CBL,
EZH2 and IDH (Tefferi, 2010). Therefore, it will be of considerable
interest to uncover additional genetic events acquired in the mice
that transform to PV or myelofibrosis. Furthermore, if it turns out
that the human JAK2V617F protein is fully functional in the mouse
environment, then it would be predicted that mice expressing
homozygous human JAK2V617F would produce a PV-like
phenotype.
In summary, it is clear that each wave of JAK2V617F mouse
models (transplantation, transgenic and knock-in) has provided
numerous insights into the cellular process of disease pathogenesis
and enhanced our understanding of the disease-initiating stem cells.
Most recently, the knock-in models have provided a system with
pathophysiological levels of JAK2V617F and have permitted higher-
resolution studies of particular cell compartments (e.g. stem and
progenitor cells). In particular, resolution of the different stem and
progenitor cell biology described in the papers by Mullally and
colleagues, and Li et al. will be key to determining how MPNs
develop and to designing future therapies. Also, as recently
proposed by Skoda, it is important to uncover why the MPN knock-
in model with the mildest phenotype appears to have a
compromised stem cell compartment (Skoda, 2010). These models
are valuable tools to further understand the molecular
consequences of MPNs, to test novel therapies and/or to identify
additional genetic events for disease progression.
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